Registre simple
dc.contributor |
Universitat de Vic. Càtedra de la Sida i Malalties Relacionades |
|
dc.contributor.author |
Negredo, Eugenia |
|
dc.contributor.author |
Diez-Pérez, Adolfo |
|
dc.contributor.author |
Bonjoch, Anna |
|
dc.contributor.author |
Domingo, Pere |
|
dc.contributor.author |
Pérez Alvarez, Núria |
|
dc.contributor.author |
Gutierrez, Mar |
|
dc.contributor.author |
Mateo, Gracia |
|
dc.contributor.author |
Puig, Jordi |
|
dc.contributor.author |
Echeverria, Patricia |
|
dc.contributor.author |
Escrig, R. |
|
dc.contributor.author |
Clotet, Bonaventura |
|
dc.date.accessioned |
2015-09-18T11:49:00Z |
|
dc.date.available |
2015-09-18T11:49:00Z |
|
dc.date.created |
2015 |
|
dc.date.issued |
2015 |
|
dc.identifier.citation |
Negredo, E., Diez-Pérez, A., Bonjoch, A., Domingo, P., Pérez-Álvarez, N., Gutierrez, M., et al. (2015). Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: Changes in bone turnover markers and circulating sclerostin levels. Journal of Antimicrobial Chemotherapy, 70(7), 2104-2107. |
ca_ES |
dc.identifier.issn |
0305-7453 |
|
dc.identifier.issn |
1460-2091 |
|
dc.identifier.uri |
http://hdl.handle.net/10854/4184 |
|
dc.description.abstract |
Background: Tenofovir is involved in accelerated bone mineral density (BMD) loss.
Methods: We recently published a hip BMD improvement at week 48 [+2.1% (95% CI: 20.6, 4.7) (P¼0.043)] in
HIV-infected patients with osteopenia/osteoporosis randomized to switch from tenofovir to abacavir (n¼26),
although without reaching statistical significance compared with those who maintained tenofovir (n¼28).
Here, we present changes at week 48 in bone markers [C-terminal telopeptide of collagen type 1 (CTX), osteocalcin
and procollagen type 1 N propeptide (P1NP)] as well as in circulating levels of three proteins involved in
bone regulation [osteoprotegerin, receptor activator for NF-kB ligand (RANKL) and sclerostin, a selective regulator
of bone formation through the Wnt pathway] in 44 of these patients. x2 or Fisher and Student t-tests were performed
according to the distribution of the variables.
Results: Bone markers decreased only in the abacavir group [mean (SD) CTX changed from 0.543 (0.495) to 0.301
(0.306) ng/mL; mean (SD) osteocalcin changed from 23.72 (22.20) to 13.95 (12.40) ng/mL; and mean (SD) P1NP
changed from 54.68 (54.52) to 28.65 (27.48) ng/mL (P,0.001 in all cases)], reaching statistical significance
between the groups at week 48. Osteoprotegerin did not vary, but sclerostin significantly increased in the abacavir
group [from 29.53 (27.91) to 35.56 (34.59) pmol/L, P¼0.002]. No significant differences in osteoprotegerin
and sclerostin were detected between the groups at week 48. RANKL values were below the limit of detection in
all samples.
Conclusions: The switch from tenofovir to abacavir seems to induce a positive effect on bone tissue, since bone
turnover markers decreased. In addition, circulating sclerostin levels increased, a change associated with
improved bone properties. |
en |
dc.format |
application/pdf |
|
dc.format.extent |
4 p. |
|
dc.language.iso |
eng |
|
dc.publisher |
Oxford University Press |
ca_ES |
dc.rights |
Tots els drets reservats |
ca_ES |
dc.rights |
(c) Oxford University Press |
|
dc.subject.other |
Sida -- Tractament |
ca_ES |
dc.title |
Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: changes in bone turnover markers and circulating sclerostin levels |
en |
dc.type |
info:eu-repo/semantics/article |
ca_ES |
dc.identifier.doi |
https://doi.org/10.1093/jac/dkv063 |
|
dc.rights.accessRights |
info:eu-repo/semantics/closedAccess |
ca_ES |
dc.type.version |
info:eu-repo/publishedVersion |
ca_ES |
dc.indexacio |
Indexat a WOS/JCR |
ca_ES |
dc.indexacio |
Indexat a SCOPUS |
ca_ES |
Text complet d'aquest document
Registre simple